Hepatitis C

Latest News

Cost-effectiveness of Total State Coverage for Hepatitis C Medications

By William V. Padula, PhD
Jonathan S. Levin, PhD

May 20th 2021

Expanded coverage under a Medicare-Medicaid partnership to treat all prevalent cases of hepatitis C appears to be cost-effective by saving money and improving patient outcomes.

Nobel Prize

Discovery of Hepatitis C Virus Brings Nobel Prize

By Mary Caffrey

October 5th 2020

HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users

HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users

By Maggie L. Shaw

April 17th 2020

Updated Hepatitis C Screening Recommendations Expand to Cover Adolescents, DAAs

Updated Hepatitis C Screening Recommendations Expand to Cover Adolescents, DAAs

By Maggie L. Shaw

March 2nd 2020

From the Editorial Board: Jeffrey D. Dunn, PharmD, MBA

By Jeffrey D. Dunn, PharmD, MBA

February 15th 2020

More News

March 24th 2015

Gilead Warns of Cardiac Issues With Sovaldi and Harvoni

The company has announced that patients on Sovaldi or Harvoni who were also on the heart medication amiodarone developed abnormally slow heartbeats. This warning by Gilead could limit the drug's use.

March 23rd 2015

Revolutionizing Treatment Outcomes in Hepatitis C: Managed Care Implications and Considerations-A Clinical Overview

Monica Shah, PharmD Zobair M. Younossi, MD, MPH, FACG, FACP, AGAF, FAASLD Yekaterina Opsha, PharmD, BCPS

March 23rd 2015

Revolutionizing Treatment Outcomes in Hepatitis C: Managed Care Implications and Considerations-Diagnosis and Management

Monica Shah, PharmD Zobair M. Younossi, MD, MPH, FACG, FACP, AGAF, FAASLD

March 23rd 2015

Post Test: Revolutionizing Treatment Outcomes in Hepatitis C: Managed Care Implications and Considerations

March 23rd 2015

Access to Low-Cost Sovaldi: Pharmacy Tourism

The global price discrimination with Sovaldi has brought to light "pharmacy tourism" - patients trying to acquire the same drug at as much as 1% of the price of the drug in the US market.

March 17th 2015

HCV Drugs Will Cost $90 Billion Over 5 Years

Laura Joszt, MA

The cost of treating the hepatitis C virus with newly approved therapies could total $90 billion over the next 5 years, representing 6.6% of the country's annual prescription spending.

March 17th 2015

With New Cholesterol Drugs, Should Managed Care Brace Itself for the Next Sovaldi?

Mary K. Caffrey

Powerful cholesterol-fighting drugs, PCSK9 inhibitors, could break new ground for payers: a higher-priced therapy could replace generic statins for patients suffering a chronic condition, perhaps for an unspecified period of time.

March 16th 2015

Participating Faculty: Revolutionizing Treatment Outcomes in Hepatitis C: Managed Care Implications and Considerations

March 10th 2015

Drug Spending Largely Driven by HCV Drugs, Compounded Medications

Laura Joszt, MA

Just 2 therapy classes are responsible for more than half of the increase in overall prescription drug spending in the United States, reported Express Scripts.

March 6th 2015

AJMC Panelists Discuss How Discounts Should Expand HCV Treatment: "It Really Is Time to Treat Everyone"

A year after Sovaldi's $1,000-a-pill price tag set off a national discussion, new entrants in the market to cure the hepatitis C virus have allowed pharmacy benefit managers to bring down its cost for health plans. Experts convened by The American Journal of Managed Care said this should expand who gets treatment, but they also say this won't be last of the high-cost specialty drugs.

March 6th 2015

NIAID Trial to Evaluate Community-Based Hepatitis C Treatment

Gilead will be providing Harvoni free of cost to conduct a 600-person trial co-sponsored by the National Institute of Allergy and Infectious Diseases to evaluate if primary care physicians and other healthcare providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians.

March 2nd 2015

Delayed HCV Treatment in Coinfected Patients Can Prove Fatal

Modeling data discussed at a press conference at the 2015 Conference on Retroviruses and Opportunistic Infections showed that delaying HCV treatment, consequent to the high cost of the newer antiviral regimens, could prove fatal in patients coninfected with HIV.

Segment 13: Making HCV Care Sustainable for All Patients

February 12th 2015

Segment 13: Making HCV Care Sustainable for All Patients

Looking at the situation in hepatitis C and its potential impact on other conditions from a provider standpoint, Ed Cohen, PharmD, FAPhA, offers up many questions to which there may not be answers just yet.

Segment 12: A New Precedent for Healthcare

February 12th 2015

Segment 12: A New Precedent for Healthcare

The situation with hepatitis C drug costs is setting an interesting precedent for the rest of healthcare and one that needs to be watched closely, according to Keith Hoffman, PhD.

Segment 11: High Cost Trends Trickling Into Other Disease Areas

February 12th 2015

Segment 11: High Cost Trends Trickling Into Other Disease Areas

Although the marketplace has managed to come to a temporary solution for the high cost of hepatitis C drugs, Steven Miller, MD, MBA, expects to see more examples of similar high-cost drugs in other categories.

Segment 10: Hepatitis C Costs in the Spotlight

February 12th 2015

Segment 10: Hepatitis C Costs in the Spotlight

In the last year the hepatitis C drug market has gained a lot of attention in the healthcare industry despite the fact that oncology as a specialty drug market has been very expensive for years now.

Segment 9: Could the Government Buy Patent Rights for Harvoni?

February 12th 2015

Segment 9: Could the Government Buy Patent Rights for Harvoni?

The idea has been floated that the government should try buying the patent rights for Harvoni from Gilead Sciences in an attempt to improve access, but even if such a move was feasible, no one seems to think it's a good idea.

Segment 8: Putting Patient Safety and Outcomes First in HCV Decisions

February 11th 2015

Segment 8: Putting Patient Safety and Outcomes First in HCV Decisions

Although the Adverse Events report found Viekira Pak may not be as safe as Sovaldi and Harvoni, Express Scripts complimented that information with its own real-world data from 85 million patients before choosing Viekira Pak.

Segment 7: Comparing Known Adverse Events of HCV Drugs

February 11th 2015

Segment 7: Comparing Known Adverse Events of HCV Drugs

A recent report from Adverse Events suggests that based on the pre-approval adverse events listed for Viekira Pak that Harvoni and Sovaldi may be safer, according to Keith Hoffman, Phd.

February 10th 2015

Gilead Faces Patent Challenge in France Over Sofosbuvir

The organization challenging Gilead is MÃ©decins du Monde (MdM), an NGO that provides healthcare for vulnerable people around the world.

Segment 2: Rational Drug Use

February 9th 2015

Segment 2: Rational Drug Use

While formularies should provide physicians the ability to treat any patient that walks into the office, there also need to be clinical exceptions that allow patients with mitigating circumstances to get any product clinically necessary.

Segment 1: Formulary Exclusivity Deals

February 9th 2015

Segment 1: Formulary Exclusivity Deals

The panelists discuss the evidence that is weighed when determining whether or not to include a particular therapy on their regimens.

February 9th 2015

New Drug Combination Promises SVR 6 in hepatitis C

Achillon's NS5A inhibitor is being evaluated with Gilead's Sovaldi in treatment-naive hepatitis C patients.

January 21st 2015

Merck's Victrelis Hepatitis C Drug Will Be Off the Market in the US

Merck this week notified the FDA that it will stop selling its Victrelis medicine in the US by the end of this year, although the drug will remain available in other countries.

January 11th 2015

Combination Therapy Eliminates HCV in Liver Transplant Patients

Laura Joszt, MA

Interferon-free combination therapy in hepatitis C patients who undergo liver transplantation can eliminate the virus, according to 2 studies published in Gastroenterology.

January 10th 2015

Anthem Selects Gilead as Primary Supplier of Hepatitis C Drugs

Health insurer Anthem Inc has reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus.

December 26th 2014

AbbVie's Hepatitis C Drug Could Put Cost Pressure on Sovaldi, Harvoni

Laura Joszt, MA

Gilead Sciences' hepatitis C drugs Sovaldi and Harvoni are the poster children for out-of-control drug costs, but competition from AbbVie's drug may place downward pressure on these prices.

December 20th 2014

Hepatitis C Patients Get Lost in the Healthcare System

Laura Joszt, MA

A new study in Hepatology highlights the need to raise awareness among healthcare professionals and at-risk populations about appropriate hepatitis C testing, referral, support, and care.

November 21st 2014

French Government Negotiates a Deal With Gilead for Sovaldi

Being promised a 100% reimbursement, Gilead will now make the drug available to HCV patients in France at 60% of the cost in the United States.

November 20th 2014

IMS Report Estimates Over A Trillion Dollars in Drug Spending This Year

According to the report, sofosbuvir for hepatitis C infections and new cancer drugs were the drivers of the high spending costs, a 7% jump over the previous year.

<1 2 3 4 5 6 7 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions